Azacitidine
Copyright policy )Azacitidine
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.
- The University of Texas MD Anderson Cancer Center United States
Antimetabolites, Antineoplastic, Clinical Trials as Topic, Treatment Outcome, Drug Design, Myelodysplastic Syndromes, Azacitidine, Humans, DNA Methylation
Antimetabolites, Antineoplastic, Clinical Trials as Topic, Treatment Outcome, Drug Design, Myelodysplastic Syndromes, Azacitidine, Humans, DNA Methylation
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).206 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!